DUSP4 and hepatocellular carcinoma: DUSP4 upregulation was observed when comparing HCC cells and HCC cells treated with 2 μM Selumetinib, indicating that MEK inhibition could upregulate DUSP4 expression in HCC cells (Figure 6B).